Tạp chí Tim mạch học Việt Nam

Article detail

Article detail description

Home
CA LÂM SÀNG Issue: Số 106 năm 2023

Case series of actue rhabdomyolysis related to statin treatment and SLCO1B1 gene polymorphism

Trần Đình Tuyên: Trường Đại học Y Hà Nội; Nguyễn Ngọc Quang: Viện Tim mạch Việt Nam, Bệnh viện Bạch Mai; Lương Thị Lan Anh: Bệnh viện Đại học Y Hà Nội;
Published: August 1, 2023
Views: 144
DOI 10.58354/jvc.106.2023.673

Abstract

The study aimed to determine the SLCO1B1 gene polymorphism in 2 cases of acute rhabdomyolysis related to statin use. This is a case series study of acute rhabdomyolysis associated with statin use and direct sequencing of the SLCO1B1 gene. The study collected 2 cases of acute rhabdomyolysis while using statins, 1 case of severe rhabdomyolysis causing acute kidney injury in patients with homozygous polymorphisms related to simvastatin, and 1 case of rhabdomyolysis had mild rhabdomyolysis with a heterozygous polymorphism associated with rosuvastatin use. Individuals with the homozygous genotype for the SLCO1B1 polymorphism experienced severe rhabdomyolysis when using simvastatin. Meanwhile, in the remaining individual using rosuvastatin with the heterozygous polymorphic gene SLCO1B1, there was a mild complication of rhabdomyolysis.

References

1.
Grundy S.M., Stone N.J., Bailey A.L., et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. J Am Coll Cardiol, 2019; 73(24).
2.
Brunham L.R., Baker S., Mammen A., et al. (2018). Role of genetics in the prediction of statin-associated muscle symptoms and optimization of statin use and adherence. Cardiovasc Res, 114(8), 1073-1081.
3.
Mach F., Baigent C., Catapano A.L., et al. (2020). 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J, 41(1), 111-188.
4.
Zineh I. (2005). HMG-CoA reductase inhibitor pharmacogenomics: overview and implications for practice. Future Cardiol, 1(2), 191-206.
5.
Ramsey L.B., Johnson S.G., Caudle K.E., et al. (2014). The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. Clin Pharmacol Ther, 96(4), 423-428.
6.
Rosenson R.S., Baker S., Banach M., et al. (2017). Optimizing Cholesterol Treatment in Patients With Muscle Complaints. J Am Coll Cardiol, 70(10), 1290-1301.
7.
Thompson P.D., Clarkson P.M., Rosenson R.S., et al. (2006). An assessment of statin safety by muscle experts. Am J Cardiol, 97(8A), 69C-76C.
8.
Ramsey L.B., Johnson S.G., Caudle K.E., et al. (2014). The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. Clin Pharmacol Ther, 96(4), 423-428.14.
9.
Brunham L.R., Lansberg P.J., Zhang L., et al. (2012). Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. Pharmacogenomics J, 12(3), 233-237.
10.
Trần Đình Tuyên và cộng sự (2020). Ảnh hưởng trên cơ vân ở bệnh nhân hội chứng vành cấp được điều trị statin và mối liên quan với gen SLCO1B1. Luận văn tốt nghiệp. Trường Đại Học Y Hà Nội
11.
Danik JS, Chasman DI, MacFadyen JG, Nyberg F, Barratt BJ, Ridker PM. Lack of association between SLCO1B1 polymorphisms and clinical myalgia following rosuvastatin therapy. Am Heart J 2013; 165: 1008-1014.15.

Files

PDF
Article Views144
Document Views1
Downloads0
Section CA LÂM SÀNG
Issue Số 106 năm 2023